Biofrontera Inc. Appoints Kevin D. Weber to its Board of Directors
08 March 2022 - 12:50AM
Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a
biopharmaceutical company specializing in the commercialization of
dermatological products, announces the appointment of Kevin D.
Weber to its Board of Directors, expanding Board membership to five
Directors.
Mr. Weber is an experienced pharmaceutical
executive who brings to Biofrontera more than 30 years of executive
and commercialization experience with a particular expertise in
product marketing. He has worked in a range of therapeutic areas
including clinical and aesthetic dermatology, pain management,
inborn errors of metabolism and respiratory medicine. He is
currently a Principal at Skysis, a biotech-focused brand management
consulting practice, and previously served as CEO of Paraffin
International. Prior to Paraffin, Mr. Weber served in senior
executive and marketing roles at Depomed, Hyperion Therapeutics and
Medicis Pharmaceuticals. From 2016 to 2021 Mr. Weber served as a
member of the supervisory board of Biofrontera AG.
“I have already had the privilege of working
with Kevin in his supervisory board function at Biofrontera AG for
more than 5 years and his guidance across strategy and operations
was immensely valuable. He brings a wealth of expertise, with
particular strength in product positioning, pricing, managed care
contracting and reimbursement, advertising and promotion, key
opinion leader development and product launches. On behalf of the
Biofrontera Inc. Board, we’re delighted to have Kevin join us and
look forward to his valuable insight as we expand our commercial
footprint in the United States,” commented Hermann Lübbert,
Executive Chairman of Biofrontera Inc.
“I’m proud to join the Board of Biofrontera Inc.
and am fortunate to have previously worked with its executive
management. We have a strong team ready to compete aggressively in
the U.S. dermatology market with Ameluz® and Xepi®. I’m confident
in our products as well as our sales and marketing efforts that are
driving adoption of PDT for the treatment of actinic keratosis and
accelerate Xepi®'s market penetration,” said Mr. Weber.
Mr. Weber previously served on the Boards of
Directors of the American Academy of Pain Medicine Foundation, the
American Chronic Pain Association and the Arizona Bioindustry
Association. He holds a B.S. in Business Administration from
Western Michigan University.
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based
biopharmaceutical company commercializing a portfolio of
pharmaceutical products for the treatment of dermatological
conditions with a focus on PDT and topical antibiotics. The
Company’s licensed products are used for the treatment of actinic
keratoses, which are pre-cancerous skin lesions, as well as
impetigo, a bacterial skin infection. For more information, visit
www.biofrontera-us.com.
Forward-Looking Statements
Certain statements in this press release may
constitute "forward-looking statements" within the meaning of the
United States Private Securities Litigation Reform Act of 1995, as
amended to date. These statements include, but are not limited to,
statements relating to the expected trading commencement and
closing dates. We have based these forward-looking statements on
our current expectations and projections about future events,
nevertheless, actual results or events could differ materially from
the plans, intentions and expectations disclosed in, or implied by,
the forward-looking statements we make. These risks and
uncertainties, many of which are beyond our control, including, but
not limited to, the impact of extraordinary external events, such
as the current COVID-19 pandemic; any changes in the Company’s
relationship with the Licensor; the outcome of the Company’s
litigation with DUSA Pharmaceuticals, Inc., including the trial
scheduled to begin at the end of November; the Company’s ability to
achieve and sustain profitability; whether the current disruptions
in the supply chain will impact the Company’s ability to obtain and
distribute its licensed products; changes in the practices of
healthcare providers, including any changes to the coverage,
reimbursement and pricing for procedures using the Company’s
licensed products; the uncertainties inherent in the initiation and
conduct of clinical trials; availability and timing of data from
clinical trials; whether results of early clinical trials or trials
in different disease indications will be indicative of the results
of ongoing or future trials; whether results of the studies
described above will be indicative of results for any future
clinical trials and studies of Ameluz® in combination with
BF-RhodoLED®; uncertainties associated with regulatory review of
clinical trials and applications for marketing approvals; whether
the market opportunity for Ameluz® in combination with BF-RhodoLED®
is consistent with the Company’s expectations; whether the Company
will be able to successfully transition to a public company
operating independently of Biofrontera AG; the Company’s ability to
retain and hire key personnel; the sufficiency of cash resources
and need for additional financing and other factors that may be
disclosed in the Company’s filings with the SEC, which can be
obtained on the SEC website at www.sec.gov. Readers are cautioned
not to place undue reliance on the forward-looking statements,
which speak only as of the date on which they are made and reflect
management's current estimates, projections, expectations and
beliefs. The company does not plan to update any such
forward-looking statements and expressly disclaims any duty to
update the information contained in this press release except as
required by law.
Contacts
Biofrontera Inc.Anke zur
Mühlen+1 781 486 1539us-ir@biofrontera.com
LHA Investor RelationsTirth T.
Patel+1 212 201 6614tpatel@lhai.com
# # #
Biofrontera (NASDAQ:BFRIW)
Historical Stock Chart
From Sep 2024 to Oct 2024
Biofrontera (NASDAQ:BFRIW)
Historical Stock Chart
From Oct 2023 to Oct 2024